PlainRecalls
ModerateClass IITerminated

FDA Drug recall · Reported March 6, 2013

Dextroamphetamine Sulfate Extended Release Capsules, 5 mg, 90 capsules, Rx only, Manufactured by Catalent Pharma Solutions for CorePharma, LLC Middlesex, NJ 08846 NDC 64720-327-09

Failed Dissolution Specifications: The affected lots may not meet the specifications for dissolution over the product shelf life.

Recall #
D-171-2013
Affected scope
1,176 bottles
Initiated
December 4, 2012
Verify with FDA Drug →
View my saved recalls

Amedra Pharmaceuticals LLC recalled Dextroamphetamine Sulfate Extended Release Capsules, 5 mg, 90 capsules, Rx only, Manufact… — a moderate-severity action.

Dextroamphetamine Sulfate Extended Release Capsules, 5 mg, 90 capsules, Rx only, Manufact… was recalled by Amedra Pharmaceuticals LLC in March 6, 2013. Reason: Failed Dissolution Specifications: The affected lots may not meet the specifications for dissolution over the…. Check the official notice for the remedy. Verify recall #D-171-2013 with the FDA Drug before acting.

The recall

Amedra Pharmaceuticals LLC issued this moderate-severity FDA Drug recall — Failed Dissolution Specifications: The affected lots may not meet the specifications for dissolution over the….

Moderate
severity level
Class II
classification
March 6, 2013
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-171-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-171-2013) was formally reported on March 6, 2013, with the manufacturer initiating the action on December 4, 2012. It is classified under Moderate severity (Class II), with a current status of Terminated. Amedra Pharmaceuticals LLC is listed as the recalling firm, operating out of Horsham, PA. Federal records list the affected scope as 1,176 bottles.

The documented reason for this recall is: Failed Dissolution Specifications: The affected lots may not meet the specifications for dissolution over the product shelf life. Distribution data in the federal record shows the product reached: Nationwide and Puerto Rico.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug — clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category — 14,048 drugs & medications recalls on record

-50005001,0001,5002,000 20052009201220152018202120242026 216

Where this recall sits in the database

Severity2366872097High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 100,165 recalls in the database, 23,668 are high severity, 72,097 moderate, and 4,400 low. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger — we do not rank products by risk from raw recall volume.

Severity

Moderate

Affected scope

1,176 bottles

Related Recalls

6

5 from same agency

Product description

Dextroamphetamine Sulfate Extended Release Capsules, 5 mg, 90 capsules, Rx only, Manufactured by Catalent Pharma Solutions for CorePharma, LLC Middlesex, NJ 08846 NDC 64720-327-09

Reason for recall

Failed Dissolution Specifications: The affected lots may not meet the specifications for dissolution over the product shelf life.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Terminated
Recall number D-171-2013
Date reported March 6, 2013
Date initiated December 4, 2012
Recalling firm Amedra Pharmaceuticals LLC
Firm location Horsham, PA
Affected scope 1,176 bottles
Distribution Nationwide and Puerto Rico.

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-171-2013) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting — recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Dextroamphetamine Sulfate Extended Release Capsules, 5 mg, 90 capsules, Rx only, Manufactured by Catalent Pharma Solutions for CorePharma, LLC Middlesex, NJ 08846 NDC 64720-327-09. Recalled by Amedra Pharmaceuticals LLC. Units affected: 1,176 bottles.
Why was this product recalled?
Failed Dissolution Specifications: The affected lots may not meet the specifications for dissolution over the product shelf life.
Which agency issued this recall?
This recall was issued by the FDA Drug on March 6, 2013. Severity: Moderate. Recall number: D-171-2013.
Where was the recalled product distributed?
Distribution: Nationwide and Puerto Rico..
How do I check if my product is affected by a recall?
Check the product description and recall number (D-171-2013) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category — useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with Nicotine Transdermal System Patch, 14 mg, 14 patches per bo… →

Data Sources

Source: FDA, CPSC, and NHTSA federal recall databases. This recall: FDA Drug, reported March 6, 2013.

  • Source: FDA — Food and Drug Administration, openFDA Enforcement API (food, drug, and medical device recalls)
  • Source: CPSC — Consumer Product Safety Commission Recalls API (consumer product recalls and hazards)
  • Source: NHTSA — National Highway Traffic Safety Administration Recalls API (vehicle safety recalls)

Recall information is sourced from official federal agency databases. Always verify recall details with the issuing agency for the most current status. This information is for research and awareness purposes only.

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records — no number is typed in by an editor. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of June 2026.